Information Provided By:
Fly News Breaks for July 3, 2019
JAZZ
Jul 3, 2019 | 05:58 EDT
Barclays analyst Balaji Prasad says last night's Sunosi launch update from Jazz Pharmaceuticals suggests upside to his estimates. Management guided to $500M in U.S. sales by 2025, suggesting potential upside to the analyst's $300M 2025 U.S. estimate. Prasad adds that while the stock has increased ~20% in the last month, he remains confident in the opportunity and further ~15% upside implied in his price target of $164. The analyst keeps an Overweight rating on Jazz Pharmaceuticals.